Skip to main content
    M

    MannKind Corp (MNKD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.96
    -0.18 (-4.24%)

    Market Cap: $1.33B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    MannKind Corp (MNKD) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    MannKind (MNKD) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, MannKind reported EPS of -$0.07, above the -$0.08 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    45%(18/40)
    Avg Surprise
    -31.88%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.00
    Range-$0.06 - $0.04
    11 analysts
    Revenue Consensus
    $135.55M
    Range$123.33M - $148.79M
    11 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.02
    Range-$0.02 - -$0.02
    1 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago-$0.020.0%
    60d ago-$0.020.0%
    30d ago-$0.020.0%
    7d ago$0.01-500.0%
    Current-$0.02
    Revenue Consensus
    $128.60M
    Range$128.60M - $128.60M
    1 analysts

    Next Report

    MNKD has an expected report date of Feb 24, 2027.

    MNKD Earnings Call

    The latest MNKD earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, MNKD beat 18, missed 18 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $101.87M, up 24.0% from $82.13M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.07-$0.08N/A+12.50%Beat-333.3%40 up, 1 downNov 5, 2026$101.87M
    Jun 30, 2026-$0.06-$0.02N/A-200.00%Miss-220.0%4N/AAug 5, 2026$109.37M
    Mar 31, 2026-$0.02$0.01$0.00 - $0.02-398.51%Miss-150.0%30 up, 0 downMay 6, 2026$90.17M
    Dec 31, 2025-$0.05-$0.01N/A-400.00%Miss-266.7%30 up, 1 downFeb 26, 2026$111.95M
    Sep 30, 2025$0.03$0.01N/A+200.00%Beat-25.0%30 up, 0 downNov 5, 2025$82.13M
    Jun 30, 2025$0.05$0.08$0.06 - $0.10-37.50%MissN/A30 up, 0 downAug 6, 2025$76.53M
    Mar 31, 2025$0.04$0.06$0.06 - $0.06-33.33%Miss0.0%10 up, 0 downMay 8, 2025$78.35M
    Dec 31, 2024$0.03$0.04N/A-25.00%Miss+597.7%20 up, 0 downFeb 26, 2025$76.78M
    Sep 30, 2024$0.04$0.03$0.02 - $0.04+33.33%Beat+300.0%31 up, 0 downNov 7, 2024$70.08M
    Jun 30, 2024-$0.01$0.01$0.00 - $0.02-200.00%MissN/A30 up, 0 downAug 7, 2024$72.39M
    Mar 31, 2024$0.04$0.03$0.01 - $0.04+33.33%BeatN/A50 up, 0 downMay 8, 2024$66.26M
    Dec 31, 2023$0.00$0.01-$0.02 - $0.04-57.00%MissN/A61 up, 0 downFeb 27, 2024$58.47M
    Sep 30, 2023$0.01-$0.02-$0.03 - $0.00+150.00%BeatN/A60 up, 0 downNov 7, 2023$51.25M
    Jun 30, 2023-$0.02-$0.04-$0.05 - -$0.02+50.00%BeatN/A50 up, 0 downAug 7, 2023$48.61M
    Mar 31, 2023-$0.04-$0.05-$0.06 - -$0.04+20.00%BeatN/A50 up, 0 downMay 9, 2023$40.63M
    Dec 31, 2022-$0.07-$0.06-$0.08 - -$0.05-16.67%MissN/A51 up, 0 downFeb 23, 2023$36.06M
    Sep 30, 2022-$0.06-$0.08-$0.13 - -$0.03+25.00%BeatN/A50 up, 0 downNov 8, 2022$32.83M
    Jun 30, 2022-$0.11-$0.09-$0.11 - -$0.08-22.22%MissN/A50 up, 0 downAug 9, 2022$18.89M
    Mar 31, 2022-$0.10-$0.10-$0.13 - -$0.080.00%In lineN/A50 up, 0 downMay 5, 2022$11.99M
    Dec 31, 2021-$0.11-$0.07-$0.10 - -$0.05-57.14%MissN/A6N/AFeb 24, 2022$12.52M
    Sep 30, 2021-$0.04-$0.08-$0.08 - -$0.03+50.00%BeatN/A51 up, 0 downNov 9, 2021$22.21M
    Jun 30, 2021-$0.05-$0.04-$0.05 - -$0.03-25.00%MissN/A5N/AAug 11, 2021$23.28M
    Mar 31, 2021-$0.05-$0.05-$0.05 - -$0.040.00%In lineN/A4N/AMay 12, 2021$17.44M
    Dec 31, 2020-$0.06-$0.04-$0.05 - -$0.03-50.00%MissN/A5N/AFeb 25, 2021$18.44M
    Sep 30, 2020-$0.05-$0.05-$0.06 - -$0.040.00%In lineN/A5N/ANov 4, 2020$15.35M
    Jun 30, 2020-$0.05-$0.06-$0.06 - -$0.05+16.67%BeatN/A5N/AAug 5, 2020$15.11M
    Mar 31, 2020-$0.04-$0.06-$0.07 - -$0.05+33.33%BeatN/A5N/AMay 6, 2020$16.23M
    Dec 31, 2019-$0.07-$0.08-$0.09 - -$0.06+12.50%BeatN/A5N/AFeb 25, 2020$15.99M
    Sep 30, 2019-$0.07-$0.07-$0.09 - -$0.060.00%In lineN/A5N/ANov 6, 2019$14.60M
    Jun 30, 2019-$0.07-$0.08-$0.08 - -$0.06+12.50%BeatN/A4N/AAug 7, 2019$15.00M
    Mar 31, 2019-$0.08-$0.13-$0.13 - -$0.07+38.46%BeatN/A2N/AMay 7, 2019$17.45M
    Dec 31, 2018-$0.06$0.22-$0.17 - $1.00-127.27%MissN/A3N/AFeb 26, 2019$16.03M
    Sep 30, 2018-$0.15-$0.18-$0.18 - -$0.18+16.67%BeatN/A1N/ANov 1, 2018$4.47M
    Jun 30, 2018-$0.17-$0.20-$0.20 - -$0.20+15.00%BeatN/A1N/AAug 2, 2018$3.89M
    Mar 31, 2018-$0.25-$0.23-$0.23 - -$0.23-8.70%MissN/A1N/AMay 9, 2018$3.46M
    Dec 31, 2017-$0.28-$0.29-$0.29 - -$0.29+3.45%BeatN/A1N/AFeb 27, 2018$4.53M
    Sep 30, 2017-$0.31-$0.20N/A-55.00%Miss-123.8%N/AN/ANov 7, 2017$2.04M
    Jun 30, 2017-$0.34-$0.23N/A-47.83%MissN/AN/AN/AAug 7, 2017$2.16M
    Mar 31, 2017-$0.17$0.12N/A-241.67%MissN/AN/AN/AMay 10, 2017$3.01M
    Dec 31, 2016-$0.19-$0.20N/A+5.00%BeatN/AN/AN/AMar 16, 2017$12.40M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.07, within 4 cents of the year before. It was $0.46 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.07N/A
    Dec 31, 2024$0.10N/A
    Dec 31, 2023-$0.05N/A
    Dec 31, 2022-$0.34N/A
    Dec 31, 2021-$0.25N/A
    Dec 31, 2020-$0.20N/A
    Dec 31, 2019-$0.29N/A
    Dec 31, 2018-$0.63N/A
    Dec 31, 2017-$1.10-339.1%
    Dec 31, 2016$0.46N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,300 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,28810
    2026Q2Jun 30, 20268,60511
    2026Q1Mar 31, 20267,45610
    2025Q4Dec 31, 20255,9407
    2025Q3Sep 30, 20256,6279
    2025Q2Jun 30, 20256,05010
    2025Q1Mar 31, 20255,4639
    2024Q4Dec 31, 20246,7919

    2026Q3 Earnings Call

    Opening remarks

    Michael Castagna Chief Executive Officer Thank you, operator, and good afternoon, everyone. Thank you for joining us for our third quarter 2026 earnings call. I'll start with our quarter highlights, then provide some business updates, while Chris walks us through our financial results, and I'll provide some closing remarks. Last quarter, I told you we had delivered all three catalysts we laid out for 2026. This quarter is about what comes next: moving from delivering catalysts to executing against them. Before we get into the quarter, I want to take a step back and look at how far MannKind has come. Five years ago, we were a company with roughly $75 million in revenue and one commercial product. Since then, we've grown revenue at a compound annual rate of more than 40%. And this year, we expect to be close to six times that size. What I'm most proud of is how we've grown. We didn't get there on a single product or a single deal. First, our collaboration with United Therapeutics took off, and Tyvaso DPI became a blockbuster built on our DPI technology. Its royalties and manufacturing revenue have funded our transformation. We used this foundation to expand our commercial business, and today, Furoscix and Afrezza are leading our growth. That growth is now reaching the bottom line. We expect record revenue in Q4 to drive us to profitability as we close out the year. And none of this reflects our pipeline or external business development opportunities that can drive faster inorganic growth. So today, MannKind isn't a single-product story anymore. We're a diversified growth company with four FDA-approved products, no near-term IP cliffs, and no concentrated risk on any one brand or therapeutic area. Today, we have three value engines driving growth. Each one plays a different role. First, we hit the key milestones laid out this year, and our commercial launches are growing nicely. Furoscix ReadyFlow is off to an exceptional start, with rapid conversion from the On-body Infuser and new patient growth. And the Afrezza pediatric launch is seeing strong early adoption. Second, our license agreement with United Therapeutics provides MannKind with cash flow that funds development and will start to drop to the bottom line in 2027 and beyond. We anticipate $15 million in milestones from ralinepag DPI in 2027. Third, our DPI platform provides upside. This is long-term value creation. Nintedanib DPI is our lung-targeted approach to IPF treatment, and key clinical evidence investors should look for is the data readout we're anticipating in the first half of 2028. And with our out-licensed programs, Tyvaso DPI and ralinepag DPI give us three potential paths in IPF. Now let me hit the exciting highlights for the quarter.

    Frequently Asked Questions About MNKD

    When is MannKind's next earnings date?

    MannKind's next earnings report is expected for Feb 24, 2027.

    Did MNKD beat earnings estimates last quarter?

    Yes. MannKind reported EPS of -$0.07 for the quarter ended Sep 30, 2026, above the -$0.08 estimate, a 12.50% surprise.

    What EPS do analysts expect from MNKD next quarter?

    The consensus EPS estimate for MannKind for the quarter ending Dec 31, 2026 is $0.00 from 11 analysts, with estimates from -$0.06 to $0.04.

    How often does MNKD beat earnings estimates?

    MannKind beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -110.23%.